Drugging the undruggable, improbable new targets for lung cancer therapy
Seven days in medicine: 27 January to 2 February
4 February 2021Researchers create test to analyse SARS-CoV-2 seroprevalence
4 February 2021Drugging the undruggable, improbable new targets for lung cancer therapy
The growth of solid tumors is frequently driven by mutations in key proto-oncogenes. For non-small-cell lung cancers (NSCLC), somatic mutations in the KRAS (Kirsten RAt Sarcoma virus) gene turn it into an oncogene that renders tumors resistant to common chemotherapies like erlotinib (Tarceva) or gefitinib (Iressa).
